Intradigm Starts Over

Intradigm Corp., a drug development company focused on  RNA interference (RNAi) therapeutics, has raised $16 million in Series A recap funding co-led by Alta Partners and Frazier Healthcare Ventures. Other backers include MediBic Alliance/Daiichi and Genentech, while return backers include Emerging Technology Partners and Novartis Ventures. The company first raised VC funding in 1999, and is moving its headquarters from < ?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />Rockville, Md. to Palo Alto, California.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />